Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a digestive enzyme device help pancreatitis patients tolerate tube feeds?

NCT ID NCT07583342

Symptom relief Sponsor: Northwell Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether RELiZORB, a cartridge containing fat-digesting enzymes, can help adults with moderate to severe acute pancreatitis tolerate tube feeding better. Fifteen participants in the ICU will receive the device and be monitored for how much nutrition they can take in. The goal is to see if more calories can be delivered compared to before using the device.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
RELiZORB digestive enzyme cartridge (immobilized lipase)
What this could lead to
If it works, this could offer a way to improve nutrition delivery in hospitalized pancreatitis patients who struggle with tube feeding.
What could go wrong
This is a very small, early-phase study with only 15 participants, so results may not apply broadly. The device may not significantly improve feeding tolerance.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female aged 18 + years of age * Admission to the Surgical Intensive Care Unit in the Northwell Health hospital system * Moderate to severe acute pancreatitis based on Atlanta criteria * Inability to tolerate ≥75% of goal EN (25 kcal/kg/d) Exclusion Criteria: * Moribund patients expected to expire within 120 hours * Evidence of unresolved intestinal obstruction, ischemia, bleeding, perforation, fistulas or tract discontinuity, or other contraindication for enteral nutrition * Diagnosis or evidence of C. Difficile or other gastrointestinal infection that may manifest with diarrhea * Pre-existing constipation defined as laxative or stool softener use prior to admission to the hospital * Patients receiving cancer-related treatment in the last 3 months * History of cystic fibrosis * Any other reason that the treating or investigator team considers to be a contraindication to enteral nutrition

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute pancreatitis (AP) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute pancreatitis pancreatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute pancreatitis (AP) Enhancing enteral nutrition tolerance

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Lenox Hill Hospital

    Manhattan, New York, 10075, United States

  • Long Island Jewish Medical Center

    New Hyde Park, New York, 11040, United States

  • North Shore University Hospital

    Manhasset, New York, 11030, United States

  • South Shore University Hospital

    Bay Shore, New York, 11706, United States

  • Staten Island University Hospital

    Staten Island, New York, 10305, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.